Everything but the Kitchen Sink: IoM Drug Safety Report Gives FDA Options
This article was originally published in RPM Report
Executive Summary
The Institute of Medicine's drug safety committee came down hard on FDA's efforts to make sure drugs they approve are safe and effective. But FDA dodged a bullet based on what isn't in the report.
You may also be interested in...
The New User Fee Rules: FDA Sacrifices Timeliness, Tries to Save Predictability
Janet Woodcock is returning as director of CDER at a time when the user fee program is in flux and FDA is struggling to implement new drug safety initiatives. For 2008, timeliness of reviews will slip, but with any luck, the transparency and predictability of PDUFA will continue.
The New User Fee Rules: FDA Sacrifices Timeliness, Tries to Save Predictability
Janet Woodcock is returning as director of CDER at a time when the user fee program is in flux and FDA is struggling to implement new drug safety initiatives. For 2008, timeliness of reviews will slip, but with any luck, the transparency and predictability of PDUFA will continue.
Avandia's Black Box: FDA's Office of New Drugs Wins
The decision by FDA to add another "black box" warning to GalxoSmithKline's diabetes drug shows where the drug safety group stands on the agency's totem pole.